Roche

Showing 15 posts of 710 posts found.

roche_dark_0

Roche withdraws Tecentriq combo application in first-line renal cell carcinoma

November 19, 2018
Sales and Marketing Cancer, Roche, avastin, pharma, renal cell carcinoma, tecentriq

The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with …

Roche’s eye drug beats Lucentis at Phase 2 in wet age-related macular degeneration

October 29, 2018
Research and Development, Sales and Marketing Genentech, Lucentis, Roche, eyecare, faricimab, pharma

Roche has revealed positive new Phase 2 data for faricimab (RG7716) in the treatment of neovascular (“wet”) age-related macular degeneration …

roche

Roche’s Alecensa topples Pfizer’s Xalkori in Asian patients with ALK+ advanced lung cancer

October 23, 2018
Manufacturing and Production, Research and Development Alecensa, Cancer, ESMO 2018, Roche, lung cancer, pharma

Following up on the reveal of data concerning its immunotherapy Tecentriq in combination with chemotherapy in the treatment of non-small …

roche_dark_0

Roche’s Tecentriq+chemo boosts survival in first-line non-small cell lung cancer

October 22, 2018
Research and Development, Sales and Marketing Cancer, Roche, lung cancer NSCLC, pharma, tecentriq

Roche joined other major players like Bristol-Myers Squibb in revealing strong data on their cancer immunotherapies at the European Society …

roche_dark_0

Roche signs $1 billion deal with cell therapy firm SQZ biotech

October 17, 2018
Research and Development Roche, SQZ, collaboration, deal, oncology

The Massachusetts-based cell therapy company SQZ Biotech, has announced the expansion of its collaboration with Swiss pharma giant Roche, in …

roche

Roche’s Kadcyla beats Herceptin breast cancer disease recurrence and death risk

October 16, 2018
Manufacturing and Production, Sales and Marketing Cancer, Kadcyla, Roche, breast cancer, pharma

Roche has unveiled new data for its antibody-drug conjugate Kadcyla (trastuzumab emtansine) in the treatment of patients with HER2-positive early …

roche__tree

Roche’s Ocrevus shows earlier, better outcomes in primary progressive and relapsing MS

October 11, 2018
Research and Development Ocrevus, Roche, multiple sclerosis, pharma

Roche has unveiled new five-year data from three Phase 3 open-label extension studies investigating the efficacy of Ocrevus (ocrelizumab) in …

image_readtop_2018_569751_15365546683454581

Celltrion’s Rituxan biosimilar gets unanimous backing from FDA committee

October 11, 2018
Sales and Marketing FDA, Oncologic Drugs Advisory Committee, Rituxan, Roche, Truxima

FDA approval looks to be in reach for Celltrion, as an advisory committee for the US regulator voted unanimously to …

roche_dark_0

FDA expands indication of Roche’s Hemlibra in haemophilia

October 5, 2018
Medical Communications, Sales and Marketing Hemlibra, Roche, haemophilia, pharma

The FDA has chosen to expand the label of Roche’s Hemlibra (emicizumab-kxwh), approving it for routine prophylaxis to prevent the …

Roche’s flu drug speeds up recovery in Phase III trial

October 4, 2018
Research and Development Roche, drug, flu, pharma, recovery

Swiss multinational Roche’s flu drug baloxavir marboxil significantly sped up recovery time in comparison with placebo, in people at high …

Roche acquires immuno-oncology biotech Tusk in €655m deal

October 1, 2018
Sales and Marketing Droia, Roche, Tusk, immuno-oncology, immunology, oncology

Swiss multinational Roche has acquired the privately held immuno-oncology company Tusk Therapeutics in a deal that could be worth up …

Roche’s Tecentriq+chemo combo shows first-line benefit in small cell lung cancer

September 26, 2018
Research and Development Cancer, Combo, Roche, chemotherapy, lung cancer, pharma, tecentriq

Roche has unveiled new Phase 3 data for its cancer immunotherapy Tecentriq (atezolizumab) in combination with carboplatin and etoposide chemotherapy …

Roche’s entrectinib shrinks lung tumours with two-year response duration

September 25, 2018
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, NSCLC, NSCLC< lung cancer, Roche, entrectinib

Roche was unveiled new Phase 1 and 2 data for entrectinib in the treatment of locally advanced or metastatic ROS1-positive …

alzheimers_pharmafocus_accompanying_image

A goal in mind: Transforming the way Alzheimer’s disease is diagnosed and treated

September 20, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Roche, pharma

Dr Rachelle Doody, Global Head of Neurodegeneration at Roche/Genentech, discusses key learnings from clinical trials in Alzheimer’s disease, and how …

NICE rejects Roche’s Ocrevus in primary progressive multiple sclerosis

September 10, 2018
Sales and Marketing NICE, Ocrevus, Roche, UK, multiple sclerosis, pharma

Of the 100,000 MS patients in England, around one in eight have the primary progressive form (PPMS), which brings debilitating …

The Gateway to Local Adoption Series

Latest content